Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Transactions under Novonesis' share buyback program
Please read the announcement in PDF Attachment 2025_24_Share_buyback_program
Nasdaq GlobeNewswire
12/05/2025
Trading by management and close relations of management
Please read the announcement in PDF Attachment 2025_23_Trading_By_Management
Nasdaq GlobeNewswire
12/05/2025
$101M XPRIZE HEALTHSPAN AWARDS FIRST MILESTONE WINNERS DRIVING TOWARD…
Global life expectancy has more than doubled in the last 100 years, but the quality of our health as we age has not increased at the same rate. In the U.S. there is currently a 12-year gap between life expectancy and healthy life expectancy, or the period of life free of major chronic disease or disability. Launched in November 2023, the $101M XPRIZE Healthspan is the first health-focused competition of its kind, incentivizing teams to develop proactive, accessible therapeutic solutions that…
PR Newswire
12/05/2025
Curium receives marketing authorization in Switzerland for PYLCLARI® – an…
Swissmedic grants marketing authorization for PYLCLARI ®in Switzerland b.e. Imaging is marketing authorization holder and has exclusive distribution rights for PYLCLARI® across SwitzerlandZURICH, May12, 2025(GLOBE NEWSWIRE) -- Curium announced today that it has marketing authorization in Switzerland for the distribution of PYLCLARI ®(INN: Piflufolastat ( 18 F) formerly known as ( 18 F)-DCFPyL). PYLCLARI ®is indicated for the detection of prostate-specific membrane...
Nasdaq GlobeNewswire
12/05/2025
Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including…
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of scheduleTeva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability...
Nasdaq GlobeNewswire
12/05/2025
Tiziana Life Sciences Announces Purchase of Shares by Chairman
TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital. About ForalumabForalumab, a fully human...
Nasdaq GlobeNewswire
12/05/2025
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher…
AAVantgarde Bio(AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the presentation of two abstracts at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), held May 4-8, 2025 in Salt Lake City (US).Prof. Simonelli, Head of the Ophthalmology Unit at the University Hospital of Campania “Luigi Vanvitelli” (Naples), presented safety data of...
Nasdaq GlobeNewswire
12/05/2025
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2025 OF IBA SA
– WEDNESDAY, JUNE 11, 2025, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be held onWednesday June 11, 2025 at 10:00 A.M., to deliberate on the attached agenda. The OGM will be held in person at the Company's headquarters. There will also be an online webcast, accessible upon prior registration, but it will not be possibleto vote online. This is a simple webcast. Shareholders are strongly...
Nasdaq GlobeNewswire
12/05/2025
iGarden Robotics: Expo 2025's Vision for Outdoor Living
A Delightful Outdoor Living, Freer Than Ever A Delightful Outdoor Living, Freer Than Ever With the world-record-breaking innovations under the banner "iGarden Robotics", the supercar-inspired lawn and pool robots and VR experience drew massive queues for hands-on demos. Their latest lawnmower, a Guinness World Record holder for "longest duration robotic lawn mower (prototype)," delivers 30 hours of operation per charge, while the pool-cleaning robot boasts a 40-hour…
PR Newswire
12/05/2025
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology…
"While precision medicine has gained widespread recognition, I have always believed that true healing demands an even deeper understanding — acknowledging that every stem cell is inherently unique. "While precision medicine has gained widespread recognition, I have always believed that true healing demands an even deeper understanding — acknowledging that every stem cell is inherently unique. Each of the 400+ human cell types carries distinct molecular blueprints, comprising…
PR Newswire
12/05/2025
Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T…
AERIAL is a multi-centre, dose-escalation trial designed to investigate a single intravenous dose of LEU011 following preconditioning chemotherapy in patients with refractory solid tumours. Initial proof-of-concept data for LEU011 is expected in the second half of 2025. AERIAL is a multi-centre, dose-escalation trial designed to investigate a single intravenous dose ofLEU011following preconditioning chemotherapy in patients with refractory solid tumours. Initial proof-of-concept data for...
PR Newswire
12/05/2025
AB Science reports its revenues for the year 2024 and provides an update on its…
PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of December 31, 2024, down 55% compared to December 31, 2023Cash position of 8,0 million euros as of December 31, 2024 Clinical development Masitinib platform: Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024...
Nasdaq GlobeNewswire
12/05/2025
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and…
The REAL8 trial showed that after 52 weeks, once-weekly Sogroya ®(somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin ®(somatropin) in children born small for gestational age (SGA) 1, or with Noonan syndrome (NS) 2, or with idiopathic short stature 3.Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS 2, as well as compared to lower doses of daily growth hormone in children born SGA 1.These...
Nasdaq GlobeNewswire
12/05/2025
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor…
PARIS and CAMBRIDGE, Mass., May12, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20,...
Nasdaq GlobeNewswire
12/05/2025
Alphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program…
Zabalafin Hydrogel offers the potential to be the first singular comprehensive approach to uniquely and effectively directly control the itch, stop the immuno-inflammatory cascade, and eliminate the bacterial cause and progression of AD. The CLEAR-AD1 trial is a randomized, double-blinded, vehicle-controlled study enrolling patients at two different stages of AD disease progression – one in which bacteria have contributed to the progression of AD but not yet to the infection stage, and the other…
PR Newswire
12/05/2025
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be...
Nasdaq GlobeNewswire
12/05/2025
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in…
Saint Herblain (France), May, 12 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a jointcommunicationto the medical community, have recommended a pause in the use of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ ®in elderly individuals while ongoing investigations into reported serious adverse events...
Nasdaq GlobeNewswire
12/05/2025
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations…
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025Männedorf, Switzerland, May 12, 2025 –The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the first quarter of 2025. On March 12, 2025, Tecan indicated a decline in sales in local currencies for the first half of the year...
Nasdaq GlobeNewswire
12/05/2025
AB DAO Partners with AB Charity Foundation
The forum was chaired by H.E. Bertie Ahern, Chairman of the AB Charity Foundation, former Prime Minister of Ireland, and former President of the European Commission. He delivered a keynote speech titled "Technology and Trust – A New Order for Philanthropy." The forum was chaired byH.E.Bertie Ahern , Chairman of the AB Charity Foundation, former Prime Minister ofIreland, and former President of the European Commission. He delivered a keynote speech titled"Technology and Trust – A…
PR Newswire
11/05/2025
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial…
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology responseData contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May10, 2025(GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical...
Nasdaq GlobeNewswire
10/05/2025
The Secret to Turning Back Time: DermRays Skincare Device Makes Women Look 10…
According to the DermRays R&D team, an exciting 1450nm laser skincare device is currently in development and is expected to launch later this year. "We are committed to continuously innovating to meet women's skincare needs," says Dr. Yang Lin, dermatology consultant for DermRays. "Our upcoming laser technology will further enhance skin rejuvenation, offering even more transformative results. According to the DermRays R&D team, an exciting 1450nm laser skincare device is…
PR Newswire
10/05/2025
Publication relating to transparency notifications
REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.FMR LLCOn May 2, 2025, Nyxoah received a transparency notification from FMR LLC. Based on the...
Nasdaq GlobeNewswire
09/05/2025
Oculis Publishes Invitation to the Annual General Meeting
/ ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the followinglink. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis websitehere. Oculis will...
Nasdaq GlobeNewswire
09/05/2025
FEELM Launches New Pod Solution Product Series, Empowering the Industry to Enter…
"By closely observing global market trends and policy shifts, we have continuously enhanced the competitiveness of our product solutions in recent years. We are committed to driving market success with a dual approach of 'technology+product', helping more clients seize market opportunities, control future industry trends, and gain a competitive edge," said REX Zhang, Head of Product Marketing at FEELM. "By closely observing global market trends and policy shifts, we have…
PR Newswire
09/05/2025
Altri Comunicati
